KHYG-1 and NK-92 represent different subtypes of LFA-1-mediated NK cell adhesiveness

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 1, 2011, Pages 166-178

  Suck, Garnet ^a   Tan, Suet Mien ^b   Chu, Sixian ^a   Niam, Madelaine ^a   Vararattanavech, Ardcharaporn ^b   Lim, Tsyr Jong ^a   Koh, Mickey B C ^a,c  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adhesion; Adoptive Immunotherapy; Cancer; Cell spreading; ICAM 1; Intercellular Adhesion Molecule; KHYG 1; LAK cells; Leukocyte function associated antigen; LFA 1; Lymphokine Activated Killer; Natural killer (NK) cell; NK 92

Indexed keywords

CD18 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL SPREADING; CELL STIMULATION; CELL THERAPY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; EX VIVO STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; NATURAL KILLER CELL; TARGET CELL; ANALYSIS OF VARIANCE; BIOLOGICAL THERAPY; CELL LINE; CELL MOTION; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; CELL ADHESION; CELL LINE; CELL MOVEMENT; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICROSCOPY, CONFOCAL; TISSUE THERAPY;

EID: 79957808412     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e230     Document Type: Article

References (56)

1. M. A. Caligiuri: Human natural killer cells. Blood, 112(3), 461-9 (2008)
2. M. Boyiadzis, K. A. Foon and R. B. Herberman: NK cells in cancer immunotherapy: three decades of discovery. Discov Med, 6(36), 243-8 (2006)
3. G. Suck: Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol, 16(5), 412-8 (2006) (Pubitemid 44322046)
4. D. H. McKenna, Jr., D. Sumstad, N. Bostrom, D. M. Kadidlo, S. Fautsch, S. McNearney, R. Dewaard, P. B. McGlave, D. J. Weisdorf, J. E. Wagner, J. McCullough and J. S. Miller: Good manufacturing practices production of natural killer cells for immunotherapy: a six-year singleinstitution experience. Transfusion, 47(3), 520-8 (2007)
5. S. K. Lee and S. Gasser: The role of natural killer cells in cancer therapy. Front Biosci (Elite Ed), 2, 380-91 (2010)
6. S. Gill, J. A. Olson and R. S. Negrin: Natural killer cells in allogeneic transplantation: effect on engraftment, graftversus- tumor, and graft-versus-host responses. Biol Blood Marrow Transplant, 15(7), 765-76 (2009)
7. H. Terunuma, X. Deng, Z. Dewan, S. Fujimoto and N. Yamamoto: Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol, 27(3), 93-110 (2008) (Pubitemid 351589824)
8. E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H. G. Ljunggren and M. S. Dilber: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood, 111(6), 3155-62 (2008)
9. M. Berg, A. Lundqvist, P. McCoy, Jr., L. Samsel, Y. Fan, A. Tawab and R. Childs: Clinical-grade ex vivoexpanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy, 11(3), 341-55 (2009)
10. J. S. Miller: Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential? Cytotherapy, 11(3), 259-60 (2009)
11. T. Tonn, S. Becker, R. Esser, D. Schwabe and E. Seifried: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res, 10(4), 535-44 (2001) (Pubitemid 32756192)
12. J. H. Gong, G. Maki and H. G. Klingemann: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 8(4), 652-8 (1994) (Pubitemid 24133034)
13. S. Arai, R. Meagher, M. Swearingen, H. Myint, E. Rich, J. Martinson and H. Klingemann: Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy, 10(6), 625-32 (2008)
14. M. Yagita, C. L. Huang, H. Umehara, Y. Matsuo, R. Tabata, M. Miyake, Y. Konaka and K. Takatsuki: A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia, 14(5), 922-30 (2000) (Pubitemid 30235072)
15. G. Suck, D. R. Branch, M. J. Smyth, R. G. Miller, J. Vergidis, S. Fahim and A. Keating: KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol, 33(10), 1160-71 (2005) (Pubitemid 41416964)
16. G. Suck, D. R. Branch and A. Keating: Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol, 82(5), 355-61 (2006) (Pubitemid 43932713)
17. S. Rosenberg: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst, 75(4), 595-603 (1985) (Pubitemid 16222388)
18. I. Dransfield, C. Cabanas, A. Craig and N. Hogg: Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol, 116(1), 219-26 (1992)
19. R. C. Landis, A. McDowall, C. L. Holness, A. J. Littler, D. L. Simmons and N. Hogg: Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3. J Cell Biol, 126(2), 529-37 (1994)
20. R. H. Tang, E. Tng, S. K. Law and S. M. Tan: Epitope mapping of monoclonal antibody to integrin alphaL beta2 hybrid domain suggests different requirements of affinity states for intercellular adhesion molecules (ICAM)-1 and ICAM-3 binding. J Biol Chem, 280(32), 29208-16 (2005) (Pubitemid 41161373)
21. M. Shimaoka, C. Lu, R. T. Palframan, U. H. von Andrian, A. McCormack, J. Takagi and T. A. Springer: Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci U S A, 98(11), 6009-14 (2001) (Pubitemid 32488184)
22. P. Stanley, A. Smith, A. McDowall, A. Nicol, D. Zicha and N. Hogg: Intermediate-affinity LFA-1 binds alphaactinin- 1 to control migration at the leading edge of the T cell. EMBO J, 27(1), 62-75 (2008)
23. N. Nishida, C. Xie, M. Shimaoka, Y. Cheng, T. Walz and T. A. Springer: Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity, 25(4), 583-94 (2006) (Pubitemid 44529036)
24. X. Y. Tang, Y. F. Li and S. M. Tan: Intercellular adhesion molecule-3 binding of integrin alphaL beta2 requires both extension and opening of the integrin headpiece. J Immunol, 180(7), 4793-804 (2008)
25. Y. T. Bryceson, M. E. March, D. F. Barber, H. G. Ljunggren and E. O. Long: Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med, 202(7), 1001-12 (2005) (Pubitemid 41396899)
26. Y. T. Bryceson, M. E. March, H. G. Ljunggren and E. O. Long: Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev, 214, 73-91 (2006) (Pubitemid 44707903)
27. D. F. Barber, M. Faure and E. O. Long: LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol, 173(6), 3653-9 (2004) (Pubitemid 39280725)
28. Y. K. Tam, J. A. Martinson, K. Doligosa and H. G. Klingemann: Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy, 5(3), 259-72 (2003) (Pubitemid 37086771)
29. D. M. Baume, M. A. Caligiuri, T. J. Manley, J. F. Daley and J. Ritz: Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHCrestricted cytolytic effector cells. Cell Immunol, 131(2), 352-65 (1990)
30. P. R. Fuchshuber and E. Lotzova: Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures. Lymphokine Cytokine Res, 11(5), 271-6 (1992)
31. E. G. Addison, J. North, I. Bakhsh, C. Marden, S. Haq, S. Al-Sarraj, R. Malayeri, R. G. Wickremasinghe, J. K. Davies and M. W. Lowdell: Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology, 116(3), 354-61 (2005) (Pubitemid 41532126)
32. S. D. Wright, P. E. Rao, W. C. Van Voorhis, L. S. Craigmyle, K. Iida, M. A. Talle, E. F. Westberg, G. Goldstein and S. C. Silverstein: Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci U S A, 80(18), 5699-703 (1983) (Pubitemid 14249895)
33. M. L. Tang, L. S. Kong, S. K. Law and S. M. Tan: Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun, 348(3), 1184-93 (2006) (Pubitemid 44233538)
34. D. Simmons: Cloning cell surface molecules by transient expression in mammalian cells. . In: Cellular Interactions in Development: A practical approach. Ed D. A. Hartley. IRL Press at Oxford University Press, Oxford (1993)
35. O. Ozdemir, Y. Ravindranath and S. Savasan: Cellmediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphereadjusted counts on three-color flow cytometry. Cytometry A, 56(1), 53-60 (2003) (Pubitemid 37522506)
36. S. Muto, V. Vetvicka and G. D. Ross: CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents. J Clin Immunol, 13(3), 175-84 (1993) (Pubitemid 23151222)
37. M. Stewart and N. Hogg: Regulation of leukocyte integrin function: affinity vs. avidity. J Cell Biochem, 61(4), 554-61 (1996) (Pubitemid 26240132)
38. M. K. Robinson, D. Andrew, H. Rosen, D. Brown, S. Ortlepp, P. Stephens and E. C. Butcher: Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. J Immunol, 148(4), 1080-5 (1992)
39. C. Lu, M. Ferzly, J. Takagi and T. A. Springer: Epitope mapping of antibodies to the C-terminal region of the integrin beta 2 subunit reveals regions that become exposed upon receptor activation. J Immunol, 166(9), 5629-37 (2001) (Pubitemid 32374186)
40. L. Sanchez-Martin, N. Sanchez-Sanchez, M. D. Gutierrez-Lopez, A. I. Rojo, M. Vicente-Manzanares, M. J. Perez-Alvarez, P. Sanchez-Mateos, X. R. Bustelo, A. Cuadrado, F. Sanchez-Madrid, J. L. Rodriguez-Fernandez and C. Cabanas: Signaling through the leukocyte integrin LFA-1 in T cells induces a transient activation of Rac-1 that is regulated by Vav and PI3K/Akt-1. J Biol Chem, 279(16), 16194-205 (2004) (Pubitemid 38509312)
41. P. J. Neeson, P. J. Thurlow and G. P. Jamieson: Characterization of activated lymphocyte-tumor cell adhesion. J Leukoc Biol, 67(6), 847-55 (2000)
42. Y. Matsuo and H. G. Drexler: Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res, 27(10), 935-45 (2003) (Pubitemid 36809090)
43. M. Koh, Y. Goh, P. Tan, L. Koh, W. Hwang, Y. Loh, D. Tan, H. Ng, C. Chuah, T. Lim, M. Niam, G. Suck, M. Chan, C. Phang, J. Lee, V. Wee, C. Lim, R. Yiu, G. Kam, A. Ang and Y. Linn: Stem cell transplantation programme at Singapore General Hospital. Bone Marrow Transplant, 42 Suppl 1, S121-S124 (2008)
44. A. J. Grant, R. E. Merchant and R. E. Hall: Interleukin- 2 modulates the expression of lymphocyte functionassociated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells. Immunology, 66(1), 117-24 (1989) (Pubitemid 19041617)
45. M. Vitale, C. Bottino, S. Sivori, L. Sanseverino, R. Castriconi, E. Marcenaro, R. Augugliaro, L. Moretta and A. Moretta: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complexrestricted tumor cell lysis. J Exp Med, 187(12), 2065-72 (1998) (Pubitemid 28285576)
46. G. Maki, G. Krystal, G. Dougherty, F. Takei and H. G. Klingemann: Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia, 12(10), 1565-72 (1998) (Pubitemid 28470441)
47. J. R. Woska, Jr., M. M. Morelock, D. D. Jeanfavre, G. O. Caviness, B. J. Bormann and R. Rothlein: Molecular comparison of soluble intercellular adhesion molecule (sICAM)-1 and sICAM-3 binding to lymphocyte functionassociated antigen-1. J Biol Chem, 273(8), 4725-33 (1998) (Pubitemid 28103221)
48. C. E. Green, U. Y. Schaff, M. R. Sarantos, A. F. Lum, D. E. Staunton and S. I. Simon: Dynamic shifts in LFA-1 affinity regulate neutrophil rolling, arrest, and transmigration on inflamed endothelium. Blood, 107(5), 2101-11 (2006) (Pubitemid 43289396)
49. Y. F. Li, R. H. Tang, K. J. Puan, S. K. Law and S. M. Tan: The cytosolic protein talin induces an intermediate affinity integrin alphaLbeta2. J Biol Chem, 282(33), 24310- 9 (2007)
50. M. Kim, C. V. Carman and T. A. Springer: Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science, 301(5640), 1720-5 (2003) (Pubitemid 37174365)
51. M. Cheng, S. Y. Foo, M. L. Shi, R. H. Tang, L. S. Kong, S. K. Law and S. M. Tan: Mutation of a conserved asparagine in the I-like domain promotes constitutively active integrins alphaLbeta2 and alphaIIbbeta3. J Biol Chem, 282(25), 18225-32 (2007) (Pubitemid 47100209)
52. E. M. Mace, S. J. Monkley, D. R. Critchley and F. Takei: A dual role for talin in NK cell cytotoxicity: activation of LFA-1-mediated cell adhesion and polarization of NK cells. J Immunol, 182(2), 948-56 (2009)
53. S. Dewitt and M. Hallett: Leukocyte membrane "expansion": a central mechanism for leukocyte extravasation. J Leukoc Biol, 81(5), 1160-4 (2007) (Pubitemid 46702033)
54. D. Vitolo, N. L. Vujanovic, H. Rabinowich, M. Schlesinger, R. B. Herberman and T. L. Whiteside: Rapid Il-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells. J Immunol, 151(4), 1926-37 (1993) (Pubitemid 23235665)
55. N. L. Vujanovic, H. Rabinowich, Y. J. Lee, L. Jost, R. B. Herberman and T. L. Whiteside: Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell Immunol, 151(1), 133-57 (1993) (Pubitemid 23308440)
56. L. K. Cherry, X. Li, P. Schwab, B. Lim and L. B. Klickstein: RhoH is required to maintain the integrin LFA- 1 in a nonadhesive state on lymphocytes. Nat Immunol, 5(9), 961-7 (2004) (Pubitemid 39276241)